KALA
KALA clinical trials: KALA BIO, Inc.
Every trial on ClinicalTrials.gov where KALA BIO, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 9
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
KALA on the catalyst calendar · KALA registry changes
- Primary completion Feb 5, 2020ActualPhase 3NCT03616899Safety and Efficacy of KPI-121 in Subjects With DEDKala Pharmaceuticals, Inc. · Kerato Conjunctivitis SiccaCompletedKALALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2017ActualPhase 3NCT02813265Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseaseKala Pharmaceuticals, Inc. · Dry Eye SyndromesCompletedKALALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 2NCT02218489Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland DiseaseKala Pharmaceuticals, Inc. · BlepharitisCompletedKALALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 3NCT02163824Safety and Efficacy of KPI-121 in Subjects With Postsurgical InflammationKala Pharmaceuticals, Inc. · Ocular Infections, Irritations and InflammationsCompletedKALALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2015ActualPhase 2NCT02188160Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseaseKala Pharmaceuticals, Inc. · Dry Eye SyndromesCompletedKALALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2017ActualPhase 3NCT02819284Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye DiseaseKala Pharmaceuticals, Inc. · Dry Eye SyndromesCompletedKALALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualNo phase registeredNCT02245516Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular EdemaKala Pharmaceuticals, Inc. · Retinal Vein OcclusionCompletedKALALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2017ActualPhase 3NCT02793817Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and PainKala Pharmaceuticals, Inc. · Post Surgical Ocular Inflammation and PainCompletedKALALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2018ActualPhase 3NCT03596723KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in ChildrenKala Pharmaceuticals, Inc. · Ocular InflammationTerminatedKALALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2025ActualPhase 2NCT05727878Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCEDCombangio, Inc · Persistent Corneal Epithelial DefectTerminatedKALACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2023ActualPhase 4NCT05136443Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant RejectionPrice Vision Group · Corneal Endothelial DystrophyCompletedKALACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner